Excellamol has pioneered a new class of OncoPDCs in cancer therapeutics, consisting of intrinsically disordered polypeptides, cancer cell receptor-binding ligands, and highly potent antineoplastic agents. With prolonged retention capability and target selectivity, OncoPDCs enable locoregional delivery of therapeutics to hard-to-penetrate solid tumors, enhancing efficacy while minimizing systemic toxicity. The lead clinical indications for OncoPDCs are central nervous system and pancreatic cancers.